189 related articles for article (PubMed ID: 20640868)
1. Direct costs of Alzheimer's disease in Germany.
Kiencke P; Daniel D; Grimm C; Rychlik R
Eur J Health Econ; 2011 Dec; 12(6):533-9. PubMed ID: 20640868
[TBL] [Abstract][Full Text] [Related]
2. [Cost of illness in Alzheimer's disease].
Kiencke P; Rychlik R; Grimm C; Daniel D
Med Klin (Munich); 2010 May; 105(5):327-33. PubMed ID: 20503006
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.
Vidal JS; Lacombe JM; Dartigues JF; Pasquier F; Robert P; Tzourio C; Alpérovitch A
Neuroepidemiology; 2008; 31(3):193-200. PubMed ID: 18815451
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
8. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.
Touchon J; Lachaine J; Beauchemin C; Granghaud A; Rive B; Bineau S
Eur J Health Econ; 2014 Nov; 15(8):791-800. PubMed ID: 23928827
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Pfeil AM; Kressig RW; Szucs TD
Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
[TBL] [Abstract][Full Text] [Related]
10. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Wimo A; Winblad B; Stöffler A; Wirth Y; Möbius HJ
Pharmacoeconomics; 2003; 21(5):327-40. PubMed ID: 12627986
[TBL] [Abstract][Full Text] [Related]
11. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
[TBL] [Abstract][Full Text] [Related]
12. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.
Lachaine J; Beauchemin C; Legault M; Bineau S
Can J Psychiatry; 2011 Oct; 56(10):596-604. PubMed ID: 22014692
[TBL] [Abstract][Full Text] [Related]
14. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.
Weycker D; Taneja C; Edelsberg J; Erder MH; Schmitt FA; Setyawan J; Oster G
Curr Med Res Opin; 2007 May; 23(5):1187-97. PubMed ID: 17519086
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
17. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
Truter I
Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
[TBL] [Abstract][Full Text] [Related]
18. The effect of antidementia drugs on mortality in patients with Alzheimer's disease.
Lin WH; Lin CH; Hou PH; Lan TH
J Psychopharmacol; 2019 Aug; 33(8):986-993. PubMed ID: 31084455
[TBL] [Abstract][Full Text] [Related]
19. [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009].
Marschall U; Arnold B; Häuser W
Schmerz; 2011 Aug; 25(4):402-4, 406-10. PubMed ID: 21818719
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial).
Knapp M; King D; Romeo R; Adams J; Baldwin A; Ballard C; Banerjee S; Barber R; Bentham P; Brown RG; Burns A; Dening T; Findlay D; Holmes C; Johnson T; Jones R; Katona C; Lindesay J; Macharouthu A; McKeith I; McShane R; O'Brien JT; Phillips PPJ; Sheehan B; Howard R
Int J Geriatr Psychiatry; 2017 Dec; 32(12):1205-1216. PubMed ID: 27739182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
